Stellenbosch University confirms student died of meningitis, starts contact tracing
He was found dead in his residence room over the weekend.
The university has started contract tracing.
The death of a Stellenbosch University student, whose body was found in his residence over the weekend, was due to meningococcal meningitis.
In a statement, Stellenbosch University said: 'To this background, the university confirms that it has been informed that the Matie student, who passed away over the weekend, Chris Scheffers, died of meningococcal meningitis.'
Meningitis is endemic to the Western Cape, where it circulates more commonly during the winter months. Most cases occur without a clearly identifiable source of contact.
The university said that detailed contact tracing of people who were in close contact with Scheffers over the past 10 days was under way.
A chemoprophylaxis (a preventative medication) will be issued within the next 24 hours to reduce the risk of infection.
'In this regard, Campus Health Services will directly engage with and medically advise those identified as close contacts over the next 24 hours. These include both students and staff,' the university said.
READ | 'I am so broken' - Foster mom after Maties student, 19, found dead inside campus residence
'As this strain of meningitis can spread in close-contact environments and is considered serious, the protocols of the university's Campus Health Services have been activated – guided by provincial and national health policies – with the university working in close partnership with the Western Cape government: Health and Wellness to ensure all relevant protocols and preventative measures are adhered to.
'Detailed contact tracing of people who were in close contact with Mr Scheffers over the past 10 days is under way so that chemoprophylaxis (a preventative medication) can be issued within the next 24 hours to reduce [the] risk of infection. In this regard, Campus Health Services will directly engage with and medically advise those identified as close contacts over the next 24 hours. These include both students and staff.'
The university said that no further confirmed cases had been reported, but that it 'will continue to monitor the situation and contacts very closely over the next few days'.
It continued:
If there are any concerning symptoms experienced by close contacts after receiving their chemoprophylaxis, they are advised to seek medical assessment urgently. In accordance with protocol, identified close contacts are encouraged to only attend lectures if asymptomatic, and wear masks in lectures and avoid gatherings (for example singing in groups) and not take part in contact sport.
'As a precautionary measure, all general meetings and gatherings in the Dagbreek residence (where Scheffers resided) have been postponed until the weekend.'
According to Campus Health, the bacterial infection initially presents itself with flu-like symptoms – headaches, muscle pains, joint pains and photophobia (sensitivity to light) – which then become steadily worse: high fever, severe headache, neck stiffness, vomiting, diarrhoea or stomach pains, painful joints, cold hands and feet, seizures; and/or drowsiness that can deteriorate into a coma. A red or purple rash may also appear, which does not disappear when pressed.
News24 previously reported that the second-year theology student was found dead inside his room at the Dagbreek student residence on Saturday afternoon.
Western Cape police spokesperson, Captain FC van Wyk, said when police arrived at the residence, they were escorted by security to a room on the second floor, where they found the body of the student 'lying on his back on the bed'.
Police said an inquest docket had been opened for further investigation.
The head of the Dagbreek residence, Grant Leukes, described Scheffers as an 'energetic young man' who played a 'big part' in Dagbreek's serenade group over the past two years.
'He loved the community he stayed in. We will all miss him dearly, and we send our heartfelt condolences to his family," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
15 hours ago
- Medscape
Novel Tuberculosis Shots May Benefit HIV-Positive Population
TOPLINE: A two-dose regimen of the M72/AS01 E-4, a recombinant fusion protein tuberculosis vaccine candidate, demonstrated acceptable safety and immunogenicity in virally suppressed, antiretroviral therapy (ART)-treated adolescents and adults living with HIV, showing strong antibody and CD4 T-cell responses. METHODOLOGY: Researchers conducted a randomized, phase 2 trial in South Africa to evaluate the safety and immunogenicity of the investigational M72/AS01 E-4 tuberculosis vaccine, derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) and AS01 E-4 adjuvant, in people living with HIV. tuberculosis vaccine, derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) and AS01 adjuvant, in people living with HIV. Overall, 401 participants — each on ART for ≥ 3 months with HIV viral loads < 200 copies per mL and CD4 T-cell count ≥ 200 cells per µL — were randomly assigned to receive either the M72/AS01 vaccine (n = 201; mean age, 29.4 years; 87% women) or placebo (n = 200; mean age, 29.6 years; 88% women), on days 1 and 29. Primary endpoints were the vaccine's reactogenicity and safety, assessed via solicited adverse events (AEs) within 7 days, unsolicited AEs within 28 days, and serious AEs throughout the trial. Immunogenicity was evaluated by measuring M72-specific immunoglobulin G antibody concentrations on days 1, 29, 57, 210, and 390, as well as M72-specific CD4 and CD8 T-cell responses. TAKEAWAY: Vaccine-related AEs occurred more frequently in the vaccine group (12%) than in the placebo group (6%), primarily due to a higher rate of injection-site reactions in the vaccine group (8% vs 1%). Two severe unsolicited AEs related to the vaccine were reported — a case each of dizziness and injection-site erythema, but no participant discontinued the trial or died due to AEs. Nine serious AEs occurred — four in the vaccine group (COVID-19, tibia fracture, spontaneous abortion, or psychotic disorder) and five in the placebo group (COVID-19, anal abscess, spontaneous abortion, substance-induced psychotic disorder, or physical assault); none was related to the vaccine. In the vaccine group, the geometric mean concentration of antibodies against M72 increased from the baseline level to 13.28 EU/mL by day 29, peaked at 479.70 EU/mL by day 57, and then declined to 32.43 EU/mL by day 390 — yet remained above prevaccination levels. No such increase was observed in the placebo group. The M72-specific CD4 T cells expressing interferon gamma or interleukin-2 was significantly higher in the vaccine group than in the placebo group at both day 57 and day 390 (P < .0001). IN PRACTICE: 'In conclusion, a two-dose regimen of M72/AS01 E-4 vaccine, administered 1 month apart, was well-tolerated, with an acceptable safety profile, and was immunogenic in virally suppressed, ART-treated people living with HIV aged 16-35 years,' the authors wrote. SOURCE: The study was led by Alemnew F. Dagnew, MD, Gates Medical Research Institute, Cambridge, Massachusetts. It was published online on July 1, 2025, in The Lancet HIV. LIMITATIONS: The trial population was restricted to people living with HIV who achieved viral suppression through ART, potentially limiting the generalizability of the results to those not on ART, not adhering to treatment, or newly diagnosed with HIV. Additionally, most participants were women, which may have affected overall trial outcomes given the higher risk for tuberculosis among men. DISCLOSURES: The study was funded by the Gates Foundation and the Wellcome Trust. Several authors were employees of the Gates Medical Research Institute during the trial. Some authors also received financial aid from other organizations, including Wellcome, UK Research and Innovation, Cancer Research UK, and TB Alliance. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
News24
20 hours ago
- News24
Stellenbosch University confirms student died of meningitis, starts contact tracing
A Stellenbosch University student has died of meningococcal meningitis. He was found dead in his residence room over the weekend. The university has started contract tracing. The death of a Stellenbosch University student, whose body was found in his residence over the weekend, was due to meningococcal meningitis. In a statement, Stellenbosch University said: 'To this background, the university confirms that it has been informed that the Matie student, who passed away over the weekend, Chris Scheffers, died of meningococcal meningitis.' Meningitis is endemic to the Western Cape, where it circulates more commonly during the winter months. Most cases occur without a clearly identifiable source of contact. The university said that detailed contact tracing of people who were in close contact with Scheffers over the past 10 days was under way. A chemoprophylaxis (a preventative medication) will be issued within the next 24 hours to reduce the risk of infection. 'In this regard, Campus Health Services will directly engage with and medically advise those identified as close contacts over the next 24 hours. These include both students and staff,' the university said. READ | 'I am so broken' - Foster mom after Maties student, 19, found dead inside campus residence 'As this strain of meningitis can spread in close-contact environments and is considered serious, the protocols of the university's Campus Health Services have been activated – guided by provincial and national health policies – with the university working in close partnership with the Western Cape government: Health and Wellness to ensure all relevant protocols and preventative measures are adhered to. 'Detailed contact tracing of people who were in close contact with Mr Scheffers over the past 10 days is under way so that chemoprophylaxis (a preventative medication) can be issued within the next 24 hours to reduce [the] risk of infection. In this regard, Campus Health Services will directly engage with and medically advise those identified as close contacts over the next 24 hours. These include both students and staff.' The university said that no further confirmed cases had been reported, but that it 'will continue to monitor the situation and contacts very closely over the next few days'. It continued: If there are any concerning symptoms experienced by close contacts after receiving their chemoprophylaxis, they are advised to seek medical assessment urgently. In accordance with protocol, identified close contacts are encouraged to only attend lectures if asymptomatic, and wear masks in lectures and avoid gatherings (for example singing in groups) and not take part in contact sport. 'As a precautionary measure, all general meetings and gatherings in the Dagbreek residence (where Scheffers resided) have been postponed until the weekend.' According to Campus Health, the bacterial infection initially presents itself with flu-like symptoms – headaches, muscle pains, joint pains and photophobia (sensitivity to light) – which then become steadily worse: high fever, severe headache, neck stiffness, vomiting, diarrhoea or stomach pains, painful joints, cold hands and feet, seizures; and/or drowsiness that can deteriorate into a coma. A red or purple rash may also appear, which does not disappear when pressed. News24 previously reported that the second-year theology student was found dead inside his room at the Dagbreek student residence on Saturday afternoon. Western Cape police spokesperson, Captain FC van Wyk, said when police arrived at the residence, they were escorted by security to a room on the second floor, where they found the body of the student 'lying on his back on the bed'. Police said an inquest docket had been opened for further investigation. The head of the Dagbreek residence, Grant Leukes, described Scheffers as an 'energetic young man' who played a 'big part' in Dagbreek's serenade group over the past two years. 'He loved the community he stayed in. We will all miss him dearly, and we send our heartfelt condolences to his family," he said.
Medscape
2 days ago
- Medscape
ART-Treated Children Remain at Risk for Vascular Disease
Children born with HIV and treated early with antiretroviral therapy (ART) continued to show elevated immune markers in adolescence, based on data presented at the International AIDS Society Conference on HIV Science. Although universal early ART has improved long-term health outcomes for children with perinatal HIV, data on long-term effects of ART exposure are limited, wrote Claire Davies, PhD, a researcher at Stellenbosch University, Cape Town, South Africa, and colleagues. 'Prior to 2008-2009, antiretroviral therapy for children living with perinatal HIV was withheld until HIV disease was advanced,' Davies said in an interview. 'The reasoning was that ART, having been developed from cancer chemotherapy, had significant toxicity and it was thought best to spare infants from those toxicities until benefit clearly outweighed risk,' she said. In 2009, the landmark CHER trial showed that apparently well infants living with HIV who were given empiric ART soon after birth had approximately 400% better survival compared with those with no intervention. 'Immediate worldwide implementation of this intervention has led to emergence of an entirely new disease profile: Since 2009, early initiation of ART has been standard-of-care for perinatally-infected infants,' Davies told Medscape Medical News . 'Since early-treated children living with HIV [CHIV] would then be spared from repeated opportunistic infections and years of ongoing HIV replication, it was hoped that they would also be spared from the enormous chronic inflammation that typically accompanied those infections,' she said. Chronic inflammation that persists over years is a powerful driver of cardiovascular disease (CVD), which leads to premature strokes and heart attacks in adulthood, she emphasized. The researchers reviewed data from 185 individuals aged 7-16 years who were part of a study of early ART in South Africa. The study population included 65 CHIV and 118 HIV-unexposed children who served as control individuals. The CHIV began ART within 3 months of birth and were deemed clinically well at the time of blood testing for biomarkers. The participants underwent a median of two measures of blood serum 4 years apart, yielding a total of 321 observations; 26 biomarkers were measured. After adjusting for multiple variables, the CHIV group had significantly higher levels of C-reactive protein, soluble CD14 (a marker of monocyte activation), and vascular endothelial growth factor than the unexposed children. The researchers also found specific effects in different age groups. Levels of Monocyte chemoattractant protein-1 (MCP-1), interleukin 6, and P-selectin in CHIV aged 6-8 years were significantly higher than matched control individuals, whereas MCP-1 was significantly higher in the CHIV group aged 13-16 years than control individuals. No other significant differences in biomarkers appeared between the groups. When the current study began, it was entirely unknown whether early-treated children living with HIV would suffer from the same chronic inflammation and consequent premature CVD, or to what extent early lifelong ART might prevent CVD in these children as they grew, Davies told Medscape Medical News . 'We hoped that by removing ongoing HIV replication and opportunistic infections, children living with HIV would be spared from the chronic inflammation that drives premature CVD in early adulthood,' she said. The researchers had hoped to find that early ART had a greater impact on preventing chronic inflammation, but the results showed otherwise, said Davies. The data should alert clinicians to the increased risk for premature strokes and heart attacks in adulthood for children treated early with ART, she said. For the study population treated with ART, their chronic inflammation can no longer be a result of ongoing HIV replication and opportunistic infections because these factors are no longer present, Davies told Medscape Medical News . 'We now need to understand what is driving their ongoing chronic inflammation so that we can find treatments to help reduce it, and in so doing, reduce their risk of premature strokes and heart attacks in adulthood,' she said. ART Alone is Not Enough 'While early ART dramatically improves long-term outcomes for children born with perinatal HIV, it remains unclear whether early ART alters the long-term inflammatory and immune activation profile,' said Jason E. Zucker, MD, an assistant professor of medicine and infectious diseases specialist at Columbia University Irving Medical Center, New York City, in an interview. 'These profiles are critical, as they are linked to future risk of noncommunicable diseases, such as cardiovascular and metabolic disorders,' said Zucker, who was not involved in the study. The current study fills a key gap by examining longitudinal biomarker data to assess persistent immune dysregulation in early treated children compared with uninfected control individuals, he said. Zucker said he was slightly surprised by the findings of extensive immune activation and elevated biomarkers, into adolescence, especially those associated with monocyte activation. 'The key takeaway is that early ART alone may not fully normalize immune activation in perinatally HIV-infected children,' he said. 'The data underscore the need for long-term monitoring and potentially adjunctive interventions to mitigate inflammation and reduce future disease risk, even among virologically suppressed youth,' he added. Some limitations of the study include the modest sample size and lack of any long-term clinical outcomes, Zucker told Medscape Medical News . 'Biomarker assessments, while robust, do not confirm clinical endpoints such as actual cardiovascular events, and future research should track these cohorts longitudinally into adulthood to determine whether the observed immune profiles translate into actual disease, and explore therapeutic strategies,' he said.
